TickerGuard
Buy Day today: Neutral (56) Mixed market breadth · no major macro event
HUMA

Humacyte Inc

Healthcare · Biotechnology

0.5573$ -2.0% vs. previous close Closing price · As of: Sep 25, 2026

Statements

Income Statement

All figures as a percentage of revenue in the same period.

Tick rows to compare them in a chart (up to 4)

Income Statement HUMA
Line item 2019 2020 2021 2022 2023 2024 2025
100.0% 100.0% 100.0% 100.0% – – 100.0%
1,222.0% 3,627.0% 4,856.8% 527.5% – – 836.5%
-1,122.0% -3,527.0% -4,756.8% -427.5% – – -736.5%
1,222.0% 3,627.0% 4,856.8% 4,042.2% – – 3,400.5%
263.1% 795.5% 1,664.7% 1,462.2% – – 1,529.5%
263.1% 805.7% 1,673.0% 4,976.9% – – 4,535.2%
-1,385.0% -4,332.7% -6,429.8% -5,404.3% – – -5,271.7%
37.1% 147.7% 344.3% 396.2% – – 552.0%
-1,380.7% -4,461.7% -2,096.4% -764.5% – – -2,003.6%
– 147.7% -5,068.3% -4,868.0% – – –
-1,380.7% -4,461.7% -2,096.4% -764.5% – – -2,003.6%
-1,275.9% -3,772.6% -1,099.6% 156.2% – – -1,091.2%

Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?